Favorable outcome of intraoperative radiotherapy to the primary site in patients with metastatic prostate cancer
| Autor: | Ayataka Ishikawa, Naotaka Fukui, Toshihiro Kanda, Syohei Fukuda, Kazunori Kihara, Tomoko Kazumoto, Yukio Kageyama, Masafumi Kurosumi, Yoshihiro Saito, Yasuhisa Fujii, Yu Ohkubo |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Male medicine.medical_specialty medicine.medical_treatment 030232 urology & nephrology Disease Kaplan-Meier Estimate 03 medical and health sciences Prostate cancer Intraoperative Period 0302 clinical medicine Surgical oncology Prostate Internal medicine medicine Biomarkers Tumor Humans External beam radiotherapy Stage (cooking) Aged Neoplasm Staging business.industry Prostatic Neoplasms Hematology General Medicine Middle Aged Prostate-Specific Antigen medicine.disease Prostate-specific antigen medicine.anatomical_structure Treatment Outcome 030220 oncology & carcinogenesis Surgery Radiotherapy Adjuvant business |
| Zdroj: | International journal of clinical oncology. 21(4) |
| ISSN: | 1437-7772 |
| Popis: | The aim of this study was to determine whether local radiotherapy to the prostate by intraoperative radiotherapy (IORT) increases the overall and cancer-specific survival rates of patients with metastatic prostate cancer. Between 1993 and 2000, 102 patients with prostate cancer were treated with a combination of (a) IORT of the prostate (25 or 30 Gy per fraction); (b) external beam radiotherapy of the prostate (30 Gy in 10 fractions), starting approximately 1 week post-operatively; and (c) endocrine treatment. Of these, 16 patients had stage D1 disease (D1 IORT group), 32 had stage D2 disease without visceral metastasis (D2 IORT group), and 38 had stage D2 disease without visceral metastasis and did not receive local therapy (D2 control group). Overall and cancer-specific survival rates were compared. The 5- and 10-year cancer-specific survival rates were 75.9 and 52.7 %, respectively, in the (D1 + D2) IORT group and 45.8 and 33.5 %, respectively, in the D2 control group, with cancer-specific survival being significantly longer in the D2 IORT than in the D2 control group (P = 0.030). Univariate and multivariate reduced-rank regression analyses showed that extent of skeletal disease Grade 4 and non-regional lymph node metastasis were significantly prognostic of poorer cancer-specific survival (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink